

**Summary:** Phase II Randomized, Double-Blind, Placebo And Active Controlled, Multi-Center, Parallel Group Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Chronic Low Back Pain.

**Inclusion Criteria:**

- Male or female ages 18 and over
- BMI 39 or less
- Females must use an adequate form of contraception
- Present with a duration of chronic low back pain for 3 months or longer requiring regular use of analgesic medication
- Primary location of low back pain is between the 12<sup>th</sup> thoracic vertebra and the lower gluteal folds
- A score of 4 or higher for low back pain intensity while on current treatment at screening
- Completes at least 4 daily pain diaries during the 5 days prior to randomization

**Exclusion Criteria:**

- History of lumbosacral radiculopathy, spinal stenosis associated with neurological impairment, or neurogenic claudication
- Back pain due to visceral disorder (ie, endometriosis)
- Back pain due to recent major trauma less than 6 months
- Rheumatoid arthritis
- Paget's disease
- Fibromyalgia
- Tumors or infections of the spinal cord
- Surgical intervention within the past 6 months
- Past, current or pending worker's compensation, litigation, disability, or any other monetary settlement regarding his/her low back pain or any other pain condition
- Patients receiving acetaminophen only to manage their low back pain
- Antidepressants with the exception of SSRI's on stable dose
- Systemic corticosteroid therapy within 30 days prior to screening
- Active ulcers or bleeding within 90 days of screening
- Patients with a history of unstable angina, MI, CHF, DVT or PE within 3 months of screening
- Clinically significant neurological disease

**Contact:**

Kelly Knoebber-Carr, CCRC  
Phone: 368-0746  
Email: [kknoebb@stormontvail.org](mailto:kknoebb@stormontvail.org)